DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Watch Dr. Hurvitz summarize the practice-changing data from DESTINY-Breast05 and why these findings led to updates in treatment guidelines for EBC.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
